Cover Image
市場調查報告書

肺癌治療藥的全球市場:調查與分析

Global Lung Cancer Therapeutics Market Research and Forecast, 2018-2023

出版商 Orion Market Research Pvt Ltd 商品編碼 545487
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
肺癌治療藥的全球市場:調查與分析 Global Lung Cancer Therapeutics Market Research and Forecast, 2018-2023
出版日期: 2018年03月30日 內容資訊: 英文
簡介

本報告提供肺癌治療藥的全球市場調查,提供整體市場趨勢,各治療藥·地區別的詳細趨勢,提供著治療藥的開發平台分析,已通過核准新藥概要,法規環境,市場促進·阻礙因素以及市場機會分析,競爭情形,主要企業簡介等,有系統的資訊。

第1章 報告主旨

第2章 市場概要

  • 市場定義
  • 開發平台分析
  • 分析師的見解
    • 主要的觀察
    • 建議
    • 總論
  • 法規環境
    • 美國
    • EU
    • 中國
    • 印度
    • 其他
  • 開發平台分析
    • Pembrolizumab
    • Atezolizumab
    • RG6016
    • Trastuzumab EMTANSINE
    • RG7604
    • Alectinib
    • 其他
  • 已通過核准新藥
    • ALECENSA (ALECTINIB), ROCHE
    • KEYTRUDA (PEMBROLIZUMAB), MERCK
    • OPDIVO (NIVOLUMAB), BRISTOL-MYERS SQUIBB
    • PORTRAZZA (NECITUMUMAB), ELI LILLY
    • TAGRISSO (OSIMERTINIB), ASTRAZENECA
    • ABITREXATE (METHOTREXATE)
    • AVASTIN (BEVACIZUMAB)
    • DOCETAXEL

第3章 市場決策要素

  • 推動因素
  • 阻礙因素
  • 市場機會

第4章 市場區隔

  • 肺癌治療藥市場分析
    • PLATINOL
    • TAXOL
    • GEMZAR
    • ALIMTA
    • IRESSA
    • HYCAMTIN
    • GILOTRIF
    • TAXOTERE
    • XALKORI
    • NAVELBINE
    • AVASTIN
    • TARCEVA
    • 其他

第5章 競爭分析

  • 主要策略
  • 主要企業分析

第6章 地區分析

  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第7章 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PH-1310

The global lung cancer therapeutics market is expected to grow at the CAGR of 13% during 2018-2023. The global lung cancer therapeutics market is growing at a modest rate due to rise in incidence prevalence rate of lung cancer across the globe. The adoption of lung cancer drugs and innovative lung surgeries are expected to boost the global lung cancer therapeutics market. In addition, huge demand is created by rising diagnostic centres across the globe. Investment and grants from government and private players are driving the market. Successful clinical trials and FDA approval are the key factors creating huge scope in global lung cancer therapeutics market. Number of prescriptions for lung cancer therapeutics market drugs such as Platinol, Taxol, Gemzar, Alimta, Iressa, Xalkori & Tarceva is increasing. Personalized medicines and drug discovery & development has significant contribution in the growth of lung cancer therapeutics market.

In addition, there are several other factors that are driving the market to grow such as the initiative taken by the government, rising awareness within individuals related to carcinogenic effects of smoking. Different nations imply different fines on smoking in public places. New combine therapies are being utilized for the treatment of the lung cancer. The market is also driven by the increase in the number of smokers globally. As per the Tobacco Atlas organization, in the year 2014, 5.8 trillion cigarettes were smoked globally. There are several different factors that tends to drive the market such as rising pollution due to urbanization, changing lifestyle, increasing number of lung cancer patients, and technological developments such as utilization of biomarkers for recognition of lung cancer.

North America and Europe has a considerable contribution to the growth of global lung cancer therapeutics market followed by APAC region. The key driving forces include rising incidence of lung cancer diseases and adoption of lung cancer drugs and surgeries across the globe. Emerging economies such as China, India, Japan, and Korea have most lung cancer patients and with improved healthcare system and healthcare spending APAC region looks promising for global lung cancer therapeutics market. Improved standard of living, infrastructural development and favorable government policies are some other factors that will boost the APAC market. The report includes detailed market overview, market determinants, company profiling, sector analysis, market segmentation, geographical analysis, pipeline analysis, patent analysis, strategic recommendations, key company analysis, key findings, analyst insights and predictive analysis of the market.

The global lung cancer therapeutics market companies include Boehringer Ingelheim, Abbvie, Eli Lilly, F. Hoffmann-La Roche GlaxoSmithKline, Merck Serono and Novartis. Lung cancer therapeutics companies are constantly focusing on R&D, partnerships, M&A, innovation and technological advancement.

Market Segmentation:

Global lung cancer therapeutics market by drugs includes Platinol, Taxol, Gemzar, Alimta, Iressa, Hycamtin, Gilotrif, Taxotere, Xalkori, Navelbine, Avastin, Tarceva and Others.

Global lung cancer therapeutics market by therapy include chemotherapy, targeted therapy, immunotherapy, radiation therapy, others.

Global lung cancer therapeutics market by end-user includes multi-speciality hospitals and cancer research centres.

The Report Covers:

Comprehensive research methodology of global lung cancer therapeutics market.

This report also includes detailed and extensive market overview with historical analysis & key analyst's insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global lung cancer therapeutics market.

Insights about market determinants which are stimulating the global lung cancer therapeutics market.

Detailed and extensive market segments with regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Table of Contents

CHAPTER 1. REPORT SUMMARY

1.1. RESEARCH METHODS AND TOOLS

1.2. MARKET BREAKDOWN

1.2.1. BY SEGMENTS

1.2.2. BY GEOGRAPHY

1.2.3. BY STAKEHOLDERS

1.2.4. EXCEPTIONS

CHAPTER 2. MARKET OVERVIEW AND INSIGHTS

2.1. DEFINITION

2.2. ANALYST INSIGHT

2.2.1. KEY FINDINGS & CURRENT MARKET TRENDS

2.2.2. RECOMMENDATION

2.2.3. CONCLUSION

2.3. REGULATION

2.3.1. UNITED STATES

2.3.2. EUROPEAN UNION

2.3.3. CHINA

2.3.4. INDIA

2.3.5. REST OF THE WORLD

2.4. PIPELINE ANALYSIS

2.4.1. KEYTRUDA MK-3475 NON-SMALL CELL LUNG CANCER DRUG

2.4.2. ATEZOLIZUMAB (ANTI-PDL1, RG7446, MPDL3280A) ROCHE

2.4.3. RG6016 (ROCHE)

2.4.4. TRASTUZUMAB EMTANSINE (T-DM1)

2.4.5. RG7604 PIK3CA

2.4.6. ALECTINIB (RG7853)

2.4.7. OTHERS

2.5. NEWLY APPROVED DRUGS

2.5.1. ALECENSA (ALECTINIB), ROCHE

2.5.2. KEYTRUDA (PEMBROLIZUMAB), MERCK

2.5.3. OPDIVO (NIVOLUMAB), BRISTOL-MYERS SQUIBB

2.5.4. PORTRAZZA (NECITUMUMAB), ELI LILLY

2.5.5. TAGRISSO (OSIMERTINIB), ASTRAZENECA

2.5.6. ABITREXATE (METHOTREXATE)

2.5.7. AVASTIN (BEVACIZUMAB)

2.5.8. DOCETAXEL

2.5.9. FOLEX (METHOTREXATE)

2.5.10. OTHERS

CHAPTER 3. MARKET DETERMINANT

3.1. MOTIVATORS

3.1.1. RISE IN INCIDENCE & PREVALENCE RATE OF CANCER DISEASES

3.1.2. RISE IN INVESTMENT AND GRANTS FROM GOVERNMENT AND PRIVATE PLAYERS

3.1.3. GROWTH IN PHARMACEUTICAL MARKET OF LUNG CANCER

3.1.4. ADOPTION OF INNOVATIVE LUNG SURGERY

3.1.5. REGULATORY APPROVALS TO LUNG CANCER DRUGS

3.2. RESTRAINT

3.2.1. HIGH COST OF GLOBAL LUNG CANCER DRUGS AND SURGERIES

3.2.2. REIMBURSEMENT POLICIES MAY AFFECT THE GROWTH OF THE MARKET

3.3. OPPORTUNITY

3.3.1. APAC REGION HAVE HUGE OPPORTUNITY FOR GLOBAL LUNG CANCER MARKET

3.3.2. SUCCESSFUL CLINICAL TRIALS

CHAPTER 4. MARKET SEGMENTATION

4.1. LUNG CANCER THERAPEUTICS MARKET BY DRUGS

4.1.1. PLATINOL

4.1.2. TAXOL

4.1.3. GEMZAR

4.1.4. ALIMTA

4.1.5. IRESSA

4.1.6. HYCAMTIN

4.1.7. GILOTRIF

4.1.8. TAXOTERE

4.1.9. XALKORI

4.1.10. NAVELBINE

4.1.11. AVASTIN

4.1.12. TARCEVA

4.1.13. OTHERS

4.2. GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY THERAPY

4.2.1. CHEMOTHERAPY

4.2.2. TARGETED THERAPY

4.2.3. IMMUNOTHERAPY

4.2.4. RADIATION THERAPY

4.2.5. OTHERS

4.3. GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY END USER

4.3.1. MULTISPECIALITY HOSPITALS

4.3.2. CANCER RESEARCH CENTERS

CHAPTER 5. COMPETITIVE LANDSCAPE

5.1. MARKET SHARE ANALYSIS

5.2. KEY COMPANY ANALYSIS

CHAPTER 6. REGIONAL ANALYSIS

6.1. NORTH AMERICAN

6.1.1. UNITED STATES

6.1.2. CANADA

6.2. EUROPE

6.2.1. U.K

6.2.2. GERMANY

6.2.3. ITALY

6.2.4. SPAIN

6.2.5. FRANCE

6.2.6. ROE

6.3. ASIA PACIFIC

6.3.1. INDIA

6.3.2. CHINA

6.3.3. JAPAN

6.3.4. ROAPAC

6.4. REST OF THE WORLD

CHAPTER 7. COMPANY PROFILES

7.1. ABBVIE

7.2. AGENNIX

7.3. AMGEN

7.4. ASTRAZENECA

7.5. BOEHRINGER INGELHEIM

7.6. CELGENE

7.7. CELLDEX

7.8. EISAI

7.9. ELI LILLY

7.10. F. HOFFMANN-LA ROCHE

7.11. GLAXOSMITHKLINE

7.12. HELSINN

7.13. IMCLONE

7.14. MERCK SERONO

7.15. NOVARTIS

7.16. ONCOGENEX

7.17. OSI PHARMACEUTICALS

7.18. PEREGRINE

7.19. PFIZER, INC.

7.20. PIERRE FABRE

7.21. QIAGEN

7.22. SANOFI

7.23. SYNTA

7.24. TELIK

7.25. TEVA PHARMACEUTICAL

List of Tables

  • TABLE # 1 GLOBAL LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUGS, 2017-2023 ($ MILLION)
  • TABLE # 2 GLOBAL PLATINOL MARKET RESEARCH AND ANALYSIS, 2017-2023 ($MILLION)
  • TABLE # 3 GLOBAL TAXOL MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 4 GLOBAL GEMZAR MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 5 GLOBAL ALIMTA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 6 GLOBAL IRESSA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 7 GLOBAL HYCAMTIN MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 8 GLOBAL GILOTRIF MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 9 GLOBAL TAXOTERE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 10 GLOBAL XALKORI MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 11 GLOBAL NAVELBINE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 12 GLOBAL AVASTIN MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 13 GLOBAL TARCEVA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 14 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 15 GLOBAL LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2017-2023 ($ MILLION)
  • TABLE # 1 GLOBAL CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 2 GLOBAL TARGETED THERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 3 GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 4 GLOBAL RADIATION THERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 5 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 6 GLOBAL LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
  • TABLE # 7 GLOBAL MULTISPECIALITY HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 8 GLOBAL CANCER RESEARCH CENTERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 9 GLOBAL LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLION)
  • TABLE # 10 NORTH AMERICAN LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 11 NORTH AMERICAN LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUGS, 2017-2023 ($ MILLION)
  • TABLE # 12 NORTH AMERICAN LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2017-2023 ($ MILLION)
  • TABLE # 13 NORTH AMERICAN LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
  • TABLE # 14 EUROPEAN LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 15 EUROPEAN LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUGS, 2017-2023 ($ MILLION)
  • TABLE # 16 EUROPEAN LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2017-2023 ($ MILLION)
  • TABLE # 17 EUROPEAN LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
  • TABLE # 18 APAC LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 19 APAC LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUGS, 2017-2023 ($ MILLION)
  • TABLE # 20 APAC LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2017-2023 ($ MILLION)
  • TABLE # 21 APAC LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
  • TABLE # 22 ROW LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUGS, 2017-2023 ($ MILLION)
  • TABLE # 23 ROW LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2017-2023 ($ MILLION)
  • TABLE # 24 ROW LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)

List of Figures

  • FIGURE # 1 GLOBAL LUNG CANCER THERAPEUTICS MARKET SHARE BY DRUGS, 2017 VS 2023 (%)
  • FIGURE # 2 GLOBAL LUNG CANCER THERAPEUTICS MARKET SHARE BY THERAPY, 2017 VS 2023 (%)
  • FIGURE # 3 GLOBAL LUNG CANCER THERAPEUTICS MARKET SHARE BY END-USER, 2017 VS 2023 (%)
  • FIGURE # 4 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SHARE, 2017 VS 2023 (%)
  • FIGURE # 5 US LUNG CANCER THERAPEUTICS MARKET SHARE, 2017-2023 ($ MILLION)
  • FIGURE # 6 CANADA LUNG CANCER THERAPEUTICS MARKET SHARE, 2017-2023 ($ MILLION)
  • FIGURE # 7 EUROPEAN LUNG CANCER THERAPEUTICS MARKET SHARE, 2017 VS 2023 (%)
  • FIGURE # 8 UK LUNG CANCER THERAPEUTICS MARKET SHARE, 2017-2023 ($ MILLION)
  • FIGURE # 9 FRANCE LUNG CANCER THERAPEUTICS MARKET SHARE, 2017-2023 ($ MILLION)
  • FIGURE # 10 GERMANY LUNG CANCER THERAPEUTICS MARKET SHARE, 2017-2023 ($ MILLION)
  • FIGURE # 11 ITALY LUNG CANCER THERAPEUTICS MARKET SHARE, 2017-2023 ($ MILLION)
  • FIGURE # 12 SPAIN LUNG CANCER THERAPEUTICS MARKET SHARE, 2017-2023 ($ MILLION)
  • FIGURE # 13 ROE LUNG CANCER THERAPEUTICS MARKET SHARE, 2017-2023 ($ MILLION)
  • FIGURE # 14 ASIA PACIFIC LUNG CANCER THERAPEUTICS MARKET SHARE, 2017 VS 2023 (%)
  • FIGURE # 15 INDIA LUNG CANCER THERAPEUTICS MARKET SHARE, 2017-2023 ($ MILLION)
  • FIGURE # 16 CHINA LUNG CANCER THERAPEUTICS MARKET SHARE, 2017-2023 ($ MILLION)
  • FIGURE # 17 JAPAN LUNG CANCER THERAPEUTICS MARKET SHARE, 2017-2023 ($ MILLION)
  • FIGURE # 18 ROAPAC LUNG CANCER THERAPEUTICS MARKET SHARE, 2017-2023 ($ MILLION)
  • FIGURE # 19 REST OF THE WORLD LUNG CANCER THERAPEUTICS MARKET SHARE, 2017-2023 ($ MILLION)
Back to Top